SOURCE: Dutch Gold Resources
ATLANTA, GA--(Marketwired - Aug 19, 2014) - Dutch Gold Resources, Inc. (PINKSHEETS: DGRI) (the "Company") (http://dutchgoldinc.com) today announced that it has entered into a joint venture with CEN, LLC to produce the most authoritative medical manual covering the use of marijuana as a healing modality.
The Medical Cannabis Manual is a 500 page comprehensive medical text for health care practitioners. Designed for clinical application, the Medical Cannabis Manual provides information for therapeutic use for substantiated and recognized disease entities and disorders, including recommended use guidelines, descriptions of medical cannabis strains, contraindications and adverse reactions, use with prescription and over the counter medications, and employment with alternative and complementary medicine. The Medical Cannabis Manual contains 10 quick-reference monochromatic charts and extensive research references for comprehension of the physiological basis for use of cannabinoids, making it ideal for both clinical and educational reference.
The Company intends to use the Medical Cannibis Manual to launch educational outreach programs to health care providers, dispensaries and MMJ patients. Publication of the Medical Cannibis Manual is slated for Q4 2014, as initial drafting of the manuscript has already begun.
"We recognize the pressing need for there to be a peer reviewed medical manual for health care professionals and for their patients," said Daniel Hollis, CEO of the Company. To date, physicians and patients have had to rely on anecdotal information as to proper use and side effects. The Company is committed to providing the kind of information and education that will positively impact safety and efficacy for patients.
In partnership with CEN, LLC, the Company envisions the use of the Cannabis Education Network, a comprehensive library of peer-reviewed and scientific literary and videographic articles on a vast array of genres pertaining to cannabis, as an educational resource for medical practitioners, patients, students, legal and horticulture professionals, industry owners, and scientists. Education is the most critical element of cannabis marketing because physicians and health care practitioners require published research to validate prescribing medical cannabis for patient use. Conversely, patients require scholarly and peer-reviewed articles to request prescriptions from their practitioners. Hence, the driving market force is valid, published research information.
"Education is the core of the medical cannabis initiative, providing the comprehension from which to medically validate and negotiate appropriate individual plans of care," commented one of the principals CEN, LLC, a limited liability company domiciled in Florida.
An 8K covering the details of this transaction will be filed with the Securities and Exchange Commission.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by Dutch Gold Resources, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.